Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?

Somanath, Payaningal R

Somanath, Payaningal R.

Somanath PR; Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, Georgia.

Am J Physiol Lung Cell Mol Physiol ; 319(1): L45-L47, 2020 07 01.

Article in English | MEDLINE | ID: covidwho-594646

Subject(s)

Betacoronavirus; Coronavirus Infections/drug therapy; Peptidyl-Dipeptidase A/drug effects; Pneumonia, Viral/drug therapy; Proto-Oncogene Proteins c-akt/drug effects; Angiotensin-Converting Enzyme 2; COVID-19; Humans; Inflammation/drug therapy; Pandemics; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Peptidyl-Dipeptidase A / Proto-Oncogene Proteins c-akt / Betacoronavirus Limits: Humans Language: English Journal: Am J Physiol Lung Cell Mol Physiol Journal subject: Molecular Biology / Physiology Year: 2020 Document Type: Article Affiliation country: Ajplung.00124.2020

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google